Navigation Links
Milestone achieved toward production of malaria treatment using synthetic biology and fermentation
Date:2/27/2009

EMERYVILLE, Calif., March 2, 2009 - Amyris Biotechnologies has announced the publication of an article which reveals the achievement of a significant milestone toward the production of amorphadiene, a precursor of the antimalarial agent artemisinin.

The article, "High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli" appears in PLoS ONE, an open-access journal from the Public Library of Science, chronicles the steps taken which enabled Amyris scientists to achieve a crucial milestone in the fight against malaria the production of 25 g/L of amorphadiene through E. coli fermentations.

The production of amorphadiene in E. coli was first described in 2003 but the amount produced was low (50 mg/L). This level was increased to 0.5g/L in 2006, but still 50-fold lower than target production levels. This article describes the interplay of industrial fermentation processes and synthetic biology that achieved the required 50-fold increase in production levels. This milestone acts as proof of concept that commercially relevant concentrations of artemisinin precursors can be produced by microbes for conversion to artemisinin. Publication in PLoS One ensures the information is available free of charge to all nations.

The paper can be found at http://dx.plos.org/10.1371/journal.pone.0004489.

The World Health Organization recommends artemisinin-based combination therapies (ACTs) as first-line treatment for malaria. However, supplies of plant-derived artemisinin are subject to the seasonality and volatility common to many plant-based commodities, leading to fluctuations in the price of artemisinin. Commercial scale production of semi-synthetic artemisinin would have the potential to stabilize supply and supplement existing plant-derived materials to create a consistent, high-quality and affordable new source of artemisinin to help meet the projected world-wide demand for ACTs.

The microbial production of Artemisinin precursors was originally demonstrated in the lab of Professor Jay Keasling at the University of California, Berkeley. Dr. Keasling continued the research and founded Amyris to bring the technology to the developing world.

Dr. Jack Newman, a former Post-doc in the Keasling lab and co-founder of Amyris praised the collaboration effort and the potential of the technology. "The enormous amount of work involved on the road from idea through execution is mind-boggling. I'm grateful to the dedicated team of researchers, philanthropists and visionaries that made this happen. They have demonstrated the potential of this technology to make a difference in the world."


'/>"/>

Contact: Annika Jensen-Lamka
jensen@amyris.com
510-740-7482
Amyris Biotechnologies
Source:Eurekalert

Related biology news :

1. A new milestone in the GMES Space Component Program successfully achieved
2. Secure Services Corp. Achieves Milestone in United States Identity Protection with the Launch of the SSC SHAPE Card Management Solution
3. A gentle touch for better control, a quantum mechanical con, and milestone PRL papers
4. Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen
5. Bursts of waves drive immune system soldiers toward invaders
6. MIT works toward safer gene therapy
7. A step toward tissue-engineered heart structures for children
8. Research points towards early cancer detection
9. Researchers take first steps towards spinal cord reconstruction following injury
10. Fish farms drive wild salmon populations toward extinction
11. MIT works toward engineered blood vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... United States multicenter, prospective clinical study that demonstrates the accuracy of the ... of identifying clinically significant acute bacterial and viral respiratory tract infections by ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology: